Background: Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment.
Material/methods: A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum prohepcidin levels were measured before and at the end of the study.
Results: The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P<0.01).
Conclusions: It is concluded that EPO therapy, besides enhancing erythropoiesis, modulates serum prohepcidin levels in dialysis patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prolonged tamoxifen treatment induces iron deposition and ferroptosis in the liver.
FASEB J
January 2025
Department of Nutrition, Second Military Medical University, Shanghai, China.
Tamoxifen is an inhibitor of estrogen receptors and was originally developed for breast cancer therapy. Besides, tamoxifen is widely used for Cre-estrogen receptor-mediated conditional knockout in transgenic mice. However, we found that the 3-month feeding of 0.
View Article and Find Full Text PDFHepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis.
Hepatol Commun
January 2025
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health and National Clinical Research Center of Digestive Diseases, Beijing, China.
Article Synopsis
- Hepcidin, a hormone crucial for iron regulation, is shown to play a role in liver fibrosis by preventing hepatocyte apoptosis via the PERK pathway.
- A study using CCl4-induced liver fibrosis in hepcidin knockout mice revealed that the absence of hepcidin led to more severe liver damage and increased apoptosis compared to wild-type mice.
- Transcriptomic analysis identified that the PERK molecule is upregulated in the absence of hepcidin, suggesting its involvement in regulating cell death in liver injury, highlighting hepcidin's potential as a therapeutic target for liver fibrosis.
Are the Soluble Receptors sRAGE, sRANKL, and Osteoprotegerin Associated with Anemia in Rheumatoid Arthritis?
Int J Mol Sci
November 2024
Department of Medical Biochemistry, Faculty of Pharmacy, Medical University of Plovdiv, 15A Vasil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease that can cause inflammation and lead to anemia, and this study explores how certain soluble receptors are affected in different RA patient subgroups based on anemia types and iron levels.
- The findings show higher levels of sRAGE and sRANKL in patients with anemia of chronic disease combined with iron deficiency anemia (ACD/IDA), while OPG levels decreased, indicating potential differences in disease effects between anemia types.
- The study concludes that soluble receptors like sRAGE, sRANKL, and OPG could serve as biomarkers in RA patients, helping to identify those at risk for anemia and better understand the condition's progression.
Novel loci and biomedical consequences of iron homoeostasis variation.
Commun Biol
December 2024
BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Iron homoeostasis is tightly regulated, with hepcidin and soluble transferrin receptor (sTfR) playing significant roles. However, the genetic determinants of these traits and the biomedical consequences of iron homoeostasis variation are unclear. In a meta-analysis of 12 cohorts involving 91,675 participants, we found 43 genomic loci associated with either hepcidin or sTfR concentration, of which 15 previously unreported.
View Article and Find Full Text PDFPharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Drugs R D
December 2024
Protagonist Therapeutics, Inc., 7575 Gateway Blvd, Suite 110, Newark, CA, 94560-1160, USA.
Background And Objective: Hepcidin, an endogenous peptide hormone, binds to ferroportin and is the master regulator of iron trafficking. Rusfertide, a synthetic peptide, is a potent hepcidin mimetic. Clinical studies suggest rusfertide may be effective in the treatment of polycythemia vera.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!